<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34177813</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>13</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1664-2392</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in endocrinology</Title>
          <ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inherited Thyroid Tumors With Oncocytic Change.</ArticleTitle>
        <Pagination>
          <StartPage>691979</StartPage>
          <MedlinePgn>691979</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">691979</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2021.691979</ELocationID>
        <Abstract>
          <AbstractText>Familial non-medullary thyroid carcinoma (FNMTC) corresponds to 5-10% of all follicular cell-derived carcinoma (FCDTC). Oncocytic thyroid tumors have an increased incidence in the familial context in comparison with sporadic FCDTC, encompassing benign and malignant tumors in the same family presenting with some extent of cell oxyphilia. This has triggered the interest of our and other groups to clarify the oncocytic change, looking for genetic markers that could explain the emergence of this phenotype in thyroid benign and malignant lesions, focusing on familial aggregation. Despite some advances regarding the identification of the gene associated with retinoic and interferon-induced mortality 19 (GRIM-19), as one of the key candidate genes affected in the "Tumor with Cell Oxyphilia" (TCO) locus, most of the mutations follow a pattern of "private mutations", almost exclusive to one family. Moreover, no causative genetic alterations were identified so far in most families. The incomplete penetrance of the disease, the diverse benign and malignant phenotypes in the affected familial members and the variable syndromic associations create an additional layer of complexity for studying the genetic alterations in oncocytic tumors. In the present review, we summarized the available evidence supporting genomic-based mechanisms for the oncocytic change, particularly in the context of FNMTC. We have also addressed the challenges and gaps in the aforementioned mechanisms, as well as molecular clues that can explain, at least partially, the phenotype of oncocytic tumors and the respective clinico-pathological behavior. Finally, we pointed to areas of further investigation in the field of oncocytic (F)NMTC with translational potential in terms of therapy.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Correia, Lima, Batista, Máximo and Sobrinho-Simões.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Correia</LastName>
            <ForeName>Marcelo</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Signalling and Metabolism, Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Signalling and Metabolism, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lima</LastName>
            <ForeName>Ana Rita</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Signalling and Metabolism, Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Signalling and Metabolism, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine of the University of Porto (FMUP), Porto, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Batista</LastName>
            <ForeName>Rui</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Signalling and Metabolism, Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Signalling and Metabolism, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Máximo</LastName>
            <ForeName>Valdemar</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Signalling and Metabolism, Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Signalling and Metabolism, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine of the University of Porto (FMUP), Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Faculty of Medicine of the University of Porto (FMUP), Porto, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sobrinho-Simões</LastName>
            <ForeName>Manuel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Signalling and Metabolism, Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Signalling and Metabolism, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Faculty of Medicine of the University of Porto (FMUP), Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Centro Hospitalar e Universitário São João (CHUSJ), Porto, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Endocrinol (Lausanne)</MedlineTA>
        <NlmUniqueID>101555782</NlmUniqueID>
        <ISSNLinking>1664-2392</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054629" MajorTopicYN="N">Genome, Mitochondrial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024862" MajorTopicYN="N">Oxyphil Cells</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Hürthle cell</Keyword>
        <Keyword MajorTopicYN="Y">TCO locus</Keyword>
        <Keyword MajorTopicYN="Y">genetic predisposition</Keyword>
        <Keyword MajorTopicYN="Y">mitochondria</Keyword>
        <Keyword MajorTopicYN="Y">oncocytic thyroid tumors</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>28</Day>
          <Hour>5</Hour>
          <Minute>55</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34177813</ArticleId>
        <ArticleId IdType="pmc">PMC8220141</ArticleId>
        <ArticleId IdType="doi">10.3389/fendo.2021.691979</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Lloyd RV, Osamura RY, Klöppel G, Rosai J. Who Classification of Tumours of Endocrine Organs, 4th Edition. (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>
Chen AY, Jemal A, Ward EM. Increasing Incidence of Differentiated Thyroid Cancer in the United States, 1988-2005. Cancer (2009) 115(16):3801–7. 10.1002/cncr.24416
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.24416</ArticleId>
            <ArticleId IdType="pubmed">19598221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Davies L, Welch HG. Increasing Incidence of Thyroid Cancer in the United States, 1973-2002. JAMA (2006) 295(18):2164–7. 10.1001/jama.295.18.2164
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.295.18.2164</ArticleId>
            <ArticleId IdType="pubmed">16684987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Grossman RF, Tu SH, Duh QY, Siperstein AE, Novosolov F, Clark OH. Familial Nonmedullary Thyroid Cancer. An Emerging Entity That Warrants Aggressive Treatment. Arch Surg (1995) 130(8):892–7. discussion 8-9. 10.1001/archsurg.1995.01430080094015
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archsurg.1995.01430080094015</ArticleId>
            <ArticleId IdType="pubmed">7632152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vriens MR, Suh I, Moses W, Kebebew E. Clinical Features and Genetic Predisposition to Hereditary Nonmedullary Thyroid Cancer. Thyroid (2009) 19(12):1343–9. 10.1089/thy.2009.1607
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2009.1607</ArticleId>
            <ArticleId IdType="pubmed">20001717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Sigurdsson A, Bergthorsson JT, et al. . Common Variants on 9q22.33 and 14q13.3 Predispose to Thyroid Cancer in European Populations. Nat Genet (2009) 41(4):460–4. 10.1038/ng.339
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.339</ArticleId>
            <ArticleId IdType="pmc">PMC3664837</ArticleId>
            <ArticleId IdType="pubmed">19198613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Enomoto Y, Enomoto K, Uchino S, Shibuya H, Watanabe S, Noguchi S. Clinical Features, Treatment, and Long-Term Outcome of Papillary Thyroid Cancer in Children and Adolescents Without Radiation Exposure. World J Surg (2012) 36(6):1241–6. 10.1007/s00268-012-1558-4
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00268-012-1558-4</ArticleId>
            <ArticleId IdType="pubmed">22411092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Figlioli G, Kohler A, Chen B, Elisei R, Romei C, Cipollini M, et al. . Novel Genome-Wide Association Study-Based Candidate Loci for Differentiated Thyroid Cancer Risk. J Clin Endocrinol Metab (2014) 99(10):E2084–92. 10.1210/jc.2014-1734
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2014-1734</ArticleId>
            <ArticleId IdType="pubmed">25029422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kohler A, Chen B, Gemignani F, Elisei R, Romei C, Figlioli G, et al. . Genome-Wide Association Study on Differentiated Thyroid Cancer. J Clin Endocrinol Metab (2013) 98(10):E1674–81. 10.1210/jc.2013-1941
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2013-1941</ArticleId>
            <ArticleId IdType="pubmed">23894154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee YM, Yoon JH, Yi O, Sung TY, Chung KW, Kim WB, et al. . Familial History of non-Medullary Thyroid Cancer is an Independent Prognostic Factor for Tumor Recurrence in Younger Patients With Conventional Papillary Thyroid Carcinoma. J Surg Oncol (2014) 109(2):168–73. 10.1002/jso.23447
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jso.23447</ArticleId>
            <ArticleId IdType="pubmed">24132694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Capezzone M, Marchisotta S, Cantara S, Busonero G, Brilli L, Pazaitou-Panayiotou K, et al. . Familial non-Medullary Thyroid Carcinoma Displays the Features of Clinical Anticipation Suggestive of A Distinct Biological Entity. Endocrine-related Cancer (2008) 15(4):1075–81. 10.1677/ERC-08-0080
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1677/ERC-08-0080</ArticleId>
            <ArticleId IdType="pubmed">18832444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Correia M, Pinheiro P, Batista R, Soares P, Sobrinho-Simoes M, Maximo V. Etiopathogenesis of Oncocytomas. Semin Cancer Biol (2017) 47:82–94. 10.1016/j.semcancer.2017.06.014
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2017.06.014</ArticleId>
            <ArticleId IdType="pubmed">28687249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Masson G, He H, et al. . Discovery of Common Variants Associated With Low TSH Levels and Thyroid Cancer Risk. Nat Genet (2012) 44(3):319–22. 10.1038/ng.1046
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.1046</ArticleId>
            <ArticleId IdType="pmc">PMC3655412</ArticleId>
            <ArticleId IdType="pubmed">22267200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Canzian F, Amati P, Harach HR, Kraimps JL, Lesueur F, Barbier J, et al. . A Gene Predisposing to Familial Thyroid Tumors With Cell Oxyphilia Maps to Chromosome 19p13.2. Am J Hum Genet (1998) 63(6):1743–8. 10.1086/302164
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/302164</ArticleId>
            <ArticleId IdType="pmc">PMC1377646</ArticleId>
            <ArticleId IdType="pubmed">9837827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
McKay JD, Thompson D, Lesueur F, Stankov K, Pastore A, Watfah C, et al. . Evidence for Interaction Between the TCO and NMTC1 Loci in Familial Non-Medullary Thyroid Cancer. J Med Genet (2004) 41(6):407–12. 10.1136/jmg.2003.017350
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jmg.2003.017350</ArticleId>
            <ArticleId IdType="pmc">PMC1735809</ArticleId>
            <ArticleId IdType="pubmed">15173224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, et al. . Somatic and Germline Mutation in GRIM-19, a Dual Function Gene Involved in Mitochondrial Metabolism and Cell Death, is Linked to Mitochondrion-Rich (Hurthle Cell) Tumours of the Thyroid. Br J Cancer (2005) 92(10):1892–8. 10.1038/sj.bjc.6602547
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6602547</ArticleId>
            <ArticleId IdType="pmc">PMC2361763</ArticleId>
            <ArticleId IdType="pubmed">15841082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bonora E, Evangelisti C, Bonichon F, Tallini G, Romeo G. Novel Germline Variants Identified in the Inner Mitochondrial Membrane Transporter TIMM44 and Their Role in Predisposition to Oncocytic Thyroid Carcinomas. Br J Cancer (2006) 95(11):1529–36. 10.1038/sj.bjc.6603455
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6603455</ArticleId>
            <ArticleId IdType="pmc">PMC2360750</ArticleId>
            <ArticleId IdType="pubmed">17088905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Diquigiovanni C, Bergamini C, Evangelisti C, Isidori F, Vettori A, Tiso N, et al. . Mutant MYO1F Alters the Mitochondrial Network and Induces Tumor Proliferation in Thyroid Cancer. Int J Cancer (2018) 143(7):1706–19. 10.1002/ijc.31548
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.31548</ArticleId>
            <ArticleId IdType="pubmed">29672841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huang G, Lu H, Hao A, Ng DC, Ponniah S, Guo K, et al. . Grim-19, a Cell Death Regulatory Protein, is Essential for Assembly and Function of Mitochondrial Complex I. Mol Cell Biol (2004) 24(19):8447–56. 10.1128/MCB.24.19.8447-8456.2004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.24.19.8447-8456.2004</ArticleId>
            <ArticleId IdType="pmc">PMC516758</ArticleId>
            <ArticleId IdType="pubmed">15367666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alchanati I, Nallar SC, Sun P, Gao L, Hu J, Stein A, et al. . A Proteomic Analysis Reveals the Loss of Expression of the Cell Death Regulatory Gene GRIM-19 in Human Renal Cell Carcinomas. Oncogene (2006) 25(54):7138–47. 10.1038/sj.onc.1209708
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1209708</ArticleId>
            <ArticleId IdType="pubmed">16732315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gong LB, Luo XL, Liu SY, Tao DD, Gong JP, Hu JB. [Correlations of GRIM-19 and its Target Gene Product STAT3 to Malignancy of Human Colorectal Carcinoma]. Ai Zheng = Aizheng = Chin J Cancer (2007) 26(7):683–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17626740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang L, Gao L, Li Y, Lin G, Shao Y, Ji K, et al. . Effects of Plasmid-Based Stat3-Specific Short Hairpin RNA and GRIM-19 on PC-3M Tumor Cell Growth. Clin Cancer Res (2008) 14(2):559–68. 10.1158/1078-0432.CCR-07-1176
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-07-1176</ArticleId>
            <ArticleId IdType="pubmed">18223232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moreira S, Correia M, Soares P, Maximo V. Grim-19 Function in Cancer Development. Mitochondrion (2011) 11(5):693–9. 10.1016/j.mito.2011.05.011
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mito.2011.05.011</ArticleId>
            <ArticleId IdType="pubmed">21664299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu Q, Wang L, Wang Z, Yang Y, Tian J, Liu G, et al. . Grim-19 Opposes Reprogramming of Glioblastoma Cell Metabolism Via HIF1alpha Destabilization. Carcinogenesis (2013) 34(8):1728–36. 10.1093/carcin/bgt125
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgt125</ArticleId>
            <ArticleId IdType="pubmed">23580587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhang XY, Li M, Sun K, Chen XJ, Meng J, Wu L, et al. . Decreased Expression of GRIM-19 by DNA Hypermethylation Promotes Aerobic Glycolysis and Cell Proliferation in Head and Neck Squamous Cell Carcinoma. Oncotarget (2015) 6(1):101–15. 10.18632/oncotarget.2684
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.2684</ArticleId>
            <ArticleId IdType="pmc">PMC4381581</ArticleId>
            <ArticleId IdType="pubmed">25575809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kalakonda S, Nallar SC, Jaber S, Keay SK, Rorke E, Munivenkatappa R, et al. . Monoallelic Loss of Tumor Suppressor GRIM-19 Promotes Tumorigenesis in Mice. Proc Natl Acad Sci USA (2013) 110(45):E4213–22. 10.1073/pnas.1303760110
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1303760110</ArticleId>
            <ArticleId IdType="pmc">PMC3831468</ArticleId>
            <ArticleId IdType="pubmed">24145455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bonora E, Tallini G, Romeo G. Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies. J Oncol (2010) 2010:385206. 10.1155/2010/385206
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2010/385206</ArticleId>
            <ArticleId IdType="pmc">PMC2902056</ArticleId>
            <ArticleId IdType="pubmed">20628519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pradella LM, Lang M, Kurelac I, Mariani E, Guerra F, Zuntini R, et al. . Where Birt-Hogg-Dube Meets Cowden Syndrome: Mirrored Genetic Defects in Two Cases of Syndromic Oncocytic Tumours. Eur J Hum Genet (2013) 21(10):1169–72. 10.1038/ejhg.2013.8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ejhg.2013.8</ArticleId>
            <ArticleId IdType="pmc">PMC3778364</ArticleId>
            <ArticleId IdType="pubmed">23386036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nesland JM, Sobrinho-Simoes MA, Holm R, Sambade MC, Johannessen JV. Hurthle-Cell Lesions of the Thyroid: A Combined Study Using Transmission Electron Microscopy, Scanning Electron Microscopy, and Immunocytochemistry. Ultrastructural Pathol (1985) 8(4):269–90. 10.3109/01913128509141518
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/01913128509141518</ArticleId>
            <ArticleId IdType="pubmed">4082297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sobrinho-Simoes MA, Nesland JM, Holm R, Sambade MC, Johannessen JV. Hurthle Cell and Mitochondrion-Rich Papillary Carcinomas of the Thyroid Gland: An Ultrastructural and Immunocytochemical Study. Ultrastructural Pathol (1985) 8(2-3):131–42. 10.3109/01913128509142147
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/01913128509142147</ArticleId>
            <ArticleId IdType="pubmed">4060255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cavadas B, Pereira JB, Correia M, Fernandes V, Eloy C, Sobrinho-Simoes M, et al. . Genomic and Transcriptomic Characterization of the Mitochondrial-Rich Oncocytic Phenotype on a Thyroid Carcinoma Background. Mitochondrion (2018) 46:123–33. 10.1016/j.mito.2018.04.001
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mito.2018.04.001</ArticleId>
            <ArticleId IdType="pubmed">29631022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gasparre G, Hervouet E, de Laplanche E, Demont J, Pennisi LF, Colombel M, et al. . Clonal Expansion of Mutated Mitochondrial DNA is Associated With Tumor Formation and Complex I Deficiency in the Benign Renal Oncocytoma. Hum Mol Genet (2008) 17(7):986–95. 10.1093/hmg/ddm371
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddm371</ArticleId>
            <ArticleId IdType="pubmed">18156159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, et al. . Disruptive Mitochondrial DNA Mutations in Complex I Subunits are Markers of Oncocytic Phenotype in Thyroid Tumors. Proc Natl Acad Sci USA (2007) 104(21):9001–6. 10.1073/pnas.0703056104
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0703056104</ArticleId>
            <ArticleId IdType="pmc">PMC1885617</ArticleId>
            <ArticleId IdType="pubmed">17517629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M. Mitochondrial DNA Somatic Mutations (Point Mutations and Large Deletions) and Mitochondrial DNA Variants in Human Thyroid Pathology: A Study With Emphasis on Hurthle Cell Tumors. Am J Pathol (2002) 160(5):1857–65. 10.1016/S0002-9440(10)61132-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)61132-7</ArticleId>
            <ArticleId IdType="pmc">PMC1850872</ArticleId>
            <ArticleId IdType="pubmed">12000737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zimmermann FA, Mayr JA, Feichtinger R, Neureiter D, Lechner R, Koegler C, et al. . Respiratory Chain Complex I is a Mitochondrial Tumor Suppressor of Oncocytic Tumors. Front Biosci (2011) 3:315–25. 10.2741/e247
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2741/e247</ArticleId>
            <ArticleId IdType="pubmed">21196312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zimmermann FA, Mayr JA, Neureiter D, Feichtinger R, Alinger B, Jones ND, et al. . Lack of Complex I is Associated With Oncocytic Thyroid Tumours. Br J Cancer (2009) 100(9):1434–7. 10.1038/sj.bjc.6605028
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6605028</ArticleId>
            <ArticleId IdType="pmc">PMC2694433</ArticleId>
            <ArticleId IdType="pubmed">19352385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Savagner F, Franc B, Guyetant S, Rodien P, Reynier P, Malthiery Y. Defective Mitochondrial ATP Synthesis in Oxyphilic Thyroid Tumors. J Clin Endocrinol Metab (2001) 86(10):4920–5. 10.1210/jcem.86.10.7894
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.86.10.7894</ArticleId>
            <ArticleId IdType="pubmed">11600563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Savagner F, Chevrollier A, Loiseau D, Morgan C, Reynier P, Clark O, et al. . Mitochondrial Activity in XTC.UC1 Cells Derived From Thyroid Oncocytoma. Thyroid (2001) 11(4):327–33. 10.1089/10507250152039055
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/10507250152039055</ArticleId>
            <ArticleId IdType="pubmed">11349830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee J, Ham S, Lee MH, Kim SJ, Park JH, Lee SE, et al. . Dysregulation of Parkin-mediated Mitophagy in Thyroid Hurthle Cell Tumors. Carcinogenesis (2015) 36(11):1407–18. 10.1093/carcin/bgv122
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgv122</ArticleId>
            <ArticleId IdType="pubmed">26354775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee J, Yi S, Kang YE, Chang JY, Kim JT, Sul HJ, et al. . Defective Ciliogenesis in Thyroid Hurthle Cell Tumors is Associated With Increased Autophagy. Oncotarget (2016) 7(48):79117–30. 10.18632/oncotarget.12997
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.12997</ArticleId>
            <ArticleId IdType="pmc">PMC5346702</ArticleId>
            <ArticleId IdType="pubmed">27816963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yakes FM, Van Houten B. Mitochondrial DNA Damage is More Extensive and Persists Longer Than Nuclear DNA Damage in Human Cells Following Oxidative Stress. Proc Natl Acad Sci USA (1997) 94(2):514–9. 10.1073/pnas.94.2.514
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.94.2.514</ArticleId>
            <ArticleId IdType="pmc">PMC19544</ArticleId>
            <ArticleId IdType="pubmed">9012815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sabharwal SS, Schumacker PT. Mitochondrial ROS in Cancer: Initiators, Amplifiers or an Achilles’ Heel? Nat Rev Cancer (2014) 14(11):709–21. 10.1038/nrc3803
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3803</ArticleId>
            <ArticleId IdType="pmc">PMC4657553</ArticleId>
            <ArticleId IdType="pubmed">25342630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alexeyev M, Shokolenko I, Wilson G, LeDoux S. The Maintenance of Mitochondrial DNA Integrity–Critical Analysis and Update. Cold Spring Harb Perspect Biol (2013) 5(5):a012641. 10.1101/cshperspect.a012641
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a012641</ArticleId>
            <ArticleId IdType="pmc">PMC3632056</ArticleId>
            <ArticleId IdType="pubmed">23637283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maximo V, Sobrinho-Simoes M. Mitochondrial DNA ‘Common’ Deletion in Hurthle Cell Lesions of the Thyroid. J Pathol (2000) 192(4):561–2. 10.1002/1096-9896(200012)192:4&lt;561::AID-PATH790&gt;3.0.CO;2-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1096-9896(200012)192:4&lt;561::AID-PATH790&gt;3.0.CO;2-3</ArticleId>
            <ArticleId IdType="pubmed">11113879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, et al. . Integrated Genomic Analysis of Hurthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell (2018) 34(2):256–70.e5. 10.1016/j.ccell.2018.07.002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.07.002</ArticleId>
            <ArticleId IdType="pmc">PMC6247912</ArticleId>
            <ArticleId IdType="pubmed">30107176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gopal RK, Kubler K, Calvo SE, Polak P, Livitz D, Rosebrock D, et al. . Widespread Chromosomal Losses and Mitochondrial Dna Alterations as Genetic Drivers in Hurthle Cell Carcinoma. Cancer Cell (2018) 34(2):242–55 e5. 10.1016/j.ccell.2018.06.013
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.06.013</ArticleId>
            <ArticleId IdType="pmc">PMC6121811</ArticleId>
            <ArticleId IdType="pubmed">30107175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corver WE, Demmers J, Oosting J, Sahraeian S, Boot A, Ruano D, et al. . ROS-Induced Near-Homozygous Genomes in Thyroid Cancer. Endocrine-related Cancer (2018) 25(1):83–97. 10.1530/ERC-17-0288
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/ERC-17-0288</ArticleId>
            <ArticleId IdType="pubmed">29066502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corver WE, Ruano D, Weijers K, den Hartog WC, van Nieuwenhuizen MP, de Miranda N, et al. . Genome Haploidisation With Chromosome 7 Retention in Oncocytic Follicular Thyroid Carcinoma. PloS One (2012) 7(6):e38287. 10.1371/journal.pone.0038287
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0038287</ArticleId>
            <ArticleId IdType="pmc">PMC3365880</ArticleId>
            <ArticleId IdType="pubmed">22675538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corver WE, van Wezel T, Molenaar K, Schrumpf M, van den Akker B, van Eijk R, et al. . Near-Haploidization Significantly Associates With Oncocytic Adrenocortical, Thyroid, and Parathyroid Tumors But Not With Mitochondrial DNA Mutations. Genes Chromosomes Cancer (2014) 53(10):833–44. 10.1002/gcc.22194
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gcc.22194</ArticleId>
            <ArticleId IdType="pubmed">24909752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Erickson LA, Jalal SM, Goellner JR, Law ME, Harwood A, Jin L, et al. . Analysis of Hurthle Cell Neoplasms of the Thyroid by Interphase Fluorescence in Situ Hybridization. Am J Surg Pathol (2001) 25(7):911–7. 10.1097/00000478-200107000-00009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-200107000-00009</ArticleId>
            <ArticleId IdType="pubmed">11420462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Erickson LA, Jin L, Goellner JR, Lohse C, Pankratz VS, Zukerberg LR, et al. . Pathologic Features, Proliferative Activity, and Cyclin D1 Expression in Hurthle Cell Neoplasms of the Thyroid. Modern Pathol (2000) 13(2):186–92. 10.1038/modpathol.3880034
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.3880034</ArticleId>
            <ArticleId IdType="pubmed">10697277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sobrinho-Simoes M, Maximo V, Castro IV, Fonseca E, Soares P, Garcia-Rostan G, et al. . Hurthle (Oncocytic) Cell Tumors of Thyroid: Etiopathogenesis, Diagnosis and Clinical Significance. Int J Surg Pathol (2005) 13(1):29–35. 10.1177/106689690501300104
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/106689690501300104</ArticleId>
            <ArticleId IdType="pubmed">15735852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Addie RD, Kostidis S, Corver WE, Oosting J, Aminzadeh-Gohari S, Feichtinger RG, et al. . Metabolic Reprogramming Related to Whole-Chromosome Instability in Models for Hurthle Cell Carcinoma. Sci Rep (2020) 10(1):9578. 10.1038/s41598-020-66599-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-66599-1</ArticleId>
            <ArticleId IdType="pmc">PMC7293353</ArticleId>
            <ArticleId IdType="pubmed">32533088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ferreira-da-Silva A, Valacca C, Rios E, Populo H, Soares P, Sobrinho-Simoes M, et al. . Mitochondrial Dynamics Protein Drp1 is Overexpressed in Oncocytic Thyroid Tumors and Regulates Cancer Cell Migration. PloS One (2015) 10(3):e0122308. 10.1371/journal.pone.0122308
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0122308</ArticleId>
            <ArticleId IdType="pmc">PMC4379140</ArticleId>
            <ArticleId IdType="pubmed">25822260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lima AR, Santos L, Correia M, Soares P, Sobrinho-Simoes M, Melo M, et al. . Dynamin-Related Protein 1 At the Crossroads of Cancer. Genes (Basel) (2018) 9(2):115. 10.3390/genes9020115
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/genes9020115</ArticleId>
            <ArticleId IdType="pmc">PMC5852611</ArticleId>
            <ArticleId IdType="pubmed">29466320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lima AR, Correia M, Santos L, Tavares C, Rios E, Canberk S, et al. . S616-p-DRP1 Associates With Locally Invasive Behavior of Follicular Cell-Derived Thyroid Carcinoma. Endocrine (2020). 10.1007/s12020-020-02546-4
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-020-02546-4</ArticleId>
            <ArticleId IdType="pubmed">33219495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Allia E, Cassoni P, Marrocco T, Volante M, Bussolati B, Wong M, et al. . Oxyphilic and non-Oxyphilic Thyroid Carcinoma Cell Lines Differ in Expressing Apoptosis-Related Genes. J Endocrinol Invest (2003) 26(7):660–7. 10.1007/BF03347026
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF03347026</ArticleId>
            <ArticleId IdType="pubmed">14594119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Muller-Hocker J. Immunoreactivity of P53, Ki-67, and Bcl-2 in Oncocytic Adenomas and Carcinomas of the Thyroid Gland. Hum Pathol (1999) 30(8):926–33. 10.1016/S0046-8177(99)90246-0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0046-8177(99)90246-0</ArticleId>
            <ArticleId IdType="pubmed">10452505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Muller-Hocker J. Expression of Bcl-2, Bax and Fas in Oxyphil Cells of Hashimoto Thyroiditis. Virchows Archiv (2000) 436(6):602–7. 10.1007/s004280000188
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004280000188</ArticleId>
            <ArticleId IdType="pubmed">10917176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Katoh R, Harach HR, Williams ED. Solitary, Multiple, and Familial Oxyphil Tumours of the Thyroid Gland. J Pathol (1998) 186(3):292–9. 10.1002/(SICI)1096-9896(1998110)186:3&lt;292::AID-PATH190&gt;3.0.CO;2-Y
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1096-9896(1998110)186:3&lt;292::AID-PATH190&gt;3.0.CO;2-Y</ArticleId>
            <ArticleId IdType="pubmed">10211119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maximo V, Lima J, Prazeres H, Soares P, Sobrinho-Simoes M. The Biology and the Genetics of Hurthle Cell Tumors of the Thyroid. Endocrine-related Cancer (2012) 19(4):R131–47. 10.1530/ERC-11-0354
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/ERC-11-0354</ArticleId>
            <ArticleId IdType="pubmed">22514109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chidambaram NV, Angell JE, Ling W, Hofmann ER, Kalvakolanu DV. Chromosomal Localization of Human GRIM-19, a Novel IFN-beta and Retinoic Acid-Activated Regulator of Cell Death. J Interferon Cytokine Res (2000) 20(7):661–5. 10.1089/107999000414844
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/107999000414844</ArticleId>
            <ArticleId IdType="pubmed">10926209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Abu-Amero KK, Alzahrani AS, Zou M, Shi Y. Association of Mitochondrial DNA Transversion Mutations With Familial Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2 Syndrome. Oncogene (2006) 25(5):677–84. 10.1038/sj.onc.1209094
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1209094</ArticleId>
            <ArticleId IdType="pubmed">16205644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Guilmette J, Nose V. Hereditary and Familial Thyroid Tumours. Histopathology (2018) 72(1):70–81. 10.1111/his.13373
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.13373</ArticleId>
            <ArticleId IdType="pubmed">29239041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic Population-Based Assessment of Cancer Risk in First-Degree Relatives of Cancer Probands. J Natl Cancer Inst (1994) 86(21):1600–8. 10.1093/jnci/86.21.1600
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/86.21.1600</ArticleId>
            <ArticleId IdType="pubmed">7932824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Frich L, Glattre E, Akslen LA. Familial Occurrence of Nonmedullary Thyroid Cancer: A Population-Based Study of 5673 First-Degree Relatives of Thyroid Cancer Patients From Norway. Cancer Epidemiol Biomarkers Prev (2001) 10(2):113–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11219767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fallah M, Pukkala E, Tryggvadottir L, Olsen JH, Tretli S, Sundquist K, et al. . Risk of Thyroid Cancer in First-Degree Relatives of Patients With non-Medullary Thyroid Cancer by Histology Type and Age At Diagnosis: A Joint Study From Five Nordic Countries. J Med Genet (2013) 50(6):373–82. 10.1136/jmedgenet-2012-101412
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jmedgenet-2012-101412</ArticleId>
            <ArticleId IdType="pubmed">23585692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. . American Thyroid Association Management Guidelines for Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer 2015. Thyroid (2016) 26(1):1–133. 10.1089/thy.2015.0020
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2015.0020</ArticleId>
            <ArticleId IdType="pmc">PMC4739132</ArticleId>
            <ArticleId IdType="pubmed">26462967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Richards ML. Familial Syndromes Associated With Thyroid Cancer in the Era of Personalized Medicine. Thyroid (2010) 20(7):707–13. 10.1089/thy.2010.1641
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2010.1641</ArticleId>
            <ArticleId IdType="pubmed">20578894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Canberk S, Ferreira JC, Pereira L, Batista R, Vieira AF, Soares P, et al. . Analyzing the Role of DICER1 Germline Variations in Papillary Thyroid Carcinoma. Eur Thyroid J (2020) 9:296–303. 10.1159/000509183
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000509183</ArticleId>
            <ArticleId IdType="pmc">PMC7923931</ArticleId>
            <ArticleId IdType="pubmed">33718253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Haigh PI, Urbach DR. The Treatment and Prognosis of Hurthle Cell Follicular Thyroid Carcinoma Compared With its non-Hurthle Cell Counterpart. Surgery (2005) 138(6):1152–7. discussion 7-8. 10.1016/j.surg.2005.08.034
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.surg.2005.08.034</ArticleId>
            <ArticleId IdType="pubmed">16360403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
National Comprehensive Cancer Network . Thyroid Cancer (Version 3) (2019). Available at: http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf [Accessed February 18, 2021].</Citation>
        </Reference>
        <Reference>
          <Citation>
Shaha AR, Loree TR, Shah JP. Prognostic Factors and Risk Group Analysis in Follicular Carcinoma of the Thyroid. Surgery (1995) 118(6):1131–6. discussion 6-8. 10.1016/S0039-6060(05)80124-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0039-6060(05)80124-2</ArticleId>
            <ArticleId IdType="pubmed">7491533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base Report on 53,856 Cases of Thyroid Carcinoma Treated in the U.S., 1985-1995 [See Commetns]. Cancer (1998) 83(12):2638–48. 10.1002/(SICI)1097-0142(19981215)83:12&lt;2638::AID-CNCR31&gt;3.0.CO;2-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-0142(19981215)83:12&lt;2638::AID-CNCR31&gt;3.0.CO;2-1</ArticleId>
            <ArticleId IdType="pubmed">9874472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bishop JA, Wu G, Tufano RP, Westra WH. Histological Patterns of Locoregional Recurrence in Hurthle Cell Carcinoma of the Thyroid Gland. Thyroid (2012) 22(7):690–4. 10.1089/thy.2011.0407
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2011.0407</ArticleId>
            <ArticleId IdType="pubmed">22524498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chindris AM, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, et al. . Clinical and Molecular Features of Hurthle Cell Carcinoma of the Thyroid. J Clin Endocrinol Metab (2015) 100(1):55–62. 10.1210/jc.2014-1634
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2014-1634</ArticleId>
            <ArticleId IdType="pubmed">25259908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kuo EJ, Roman SA, Sosa JA. Patients With Follicular and Hurthle Cell Microcarcinomas Have Compromised Survival: A Population Level Study of 22,738 Patients. Surgery (2013) 154(6):1246–53. discussion 53-4. 10.1016/j.surg.2013.04.033
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.surg.2013.04.033</ArticleId>
            <ArticleId IdType="pubmed">23993409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mills SC, Haq M, Smellie WJ, Harmer C. Hurthle Cell Carcinoma of the Thyroid: Retrospective Review of 62 Patients Treated At the Royal Marsden Hospital Between 1946 and 2003. Eur J Surg Oncol (2009) 35(3):230–4. 10.1016/j.ejso.2008.06.007
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejso.2008.06.007</ArticleId>
            <ArticleId IdType="pubmed">18722077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Besic N, Vidergar-Kralj B, Frkovic-Grazio S, Movrin-Stanovnik T, Auersperg M. The Role of Radioactive Iodine in the Treatment of Hurthle Cell Carcinoma of the Thyroid. Thyroid (2003) 13(6):577–84. 10.1089/105072503322238845
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/105072503322238845</ArticleId>
            <ArticleId IdType="pubmed">12930602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordonez NG, et al. . Prognostic Factors in Patients With Hurthle Cell Neoplasms of the Thyroid. Cancer (2003) 97(5):1186–94. 10.1002/cncr.11176
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.11176</ArticleId>
            <ArticleId IdType="pubmed">12599224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carcangiu ML, Bianchi S, Savino D, Voynick IM, Rosai J. Follicular Hurthle Cell Tumors of the Thyroid Gland. Cancer (1991) 68(9):1944–53. 10.1002/1097-0142(19911101)68:9&lt;1944::AID-CNCR2820680917&gt;3.0.CO;2-I
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1097-0142(19911101)68:9&lt;1944::AID-CNCR2820680917&gt;3.0.CO;2-I</ArticleId>
            <ArticleId IdType="pubmed">1913544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ghossein RA, Hiltzik DH, Carlson DL, Patel S, Shaha A, Shah JP, et al. . Prognostic Factors of Recurrence in Encapsulated Hurthle Cell Carcinoma of the Thyroid Gland: A Clinicopathologic Study of 50 Cases. Cancer (2006) 106(8):1669–76. 10.1002/cncr.21825
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.21825</ArticleId>
            <ArticleId IdType="pubmed">16534796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Petric R, Gazic B, Besic N. Prognostic Factors for Disease-Specific Survival in 108 Patients With Hurthle Cell Thyroid Carcinoma: A Single-Institution Experience. BMC Cancer (2014) 14:777. 10.1186/1471-2407-14-777
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-14-777</ArticleId>
            <ArticleId IdType="pmc">PMC4213470</ArticleId>
            <ArticleId IdType="pubmed">25338674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sanders LE, Silverman M. Follicular and Hurthle Cell Carcinoma: Predicting Outcome and Directing Therapy. Surgery (1998) 124(6):967–74. 10.1016/S0039-6060(98)70036-4
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0039-6060(98)70036-4</ArticleId>
            <ArticleId IdType="pubmed">9854570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Canberk S, Lima AR, Correia M, Batista R, Soares P, Maximo V, et al. . Oncocytic Thyroid Neoplasms: From Histology to Molecular Biology. Diagn Histopathol (2019) 25(5):165–65. 10.1016/j.mpdhp.2019.02.002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mpdhp.2019.02.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kushchayeva Y, Duh QY, Kebebew E, Clark OH. Prognostic Indications for Hurthle Cell Cancer. World J Surg (2004) 28(12):1266–70. 10.1007/s00268-004-7602-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00268-004-7602-2</ArticleId>
            <ArticleId IdType="pubmed">15517492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M. Suppression of BRAF/MEK/MAP Kinase Pathway Restores Expression of Iodide-Metabolizing Genes in Thyroid Cells Expressing the V600E BRAF Mutant. Clin Cancer Res (2007) 13(4):1341–9. 10.1158/1078-0432.CCR-06-1753
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-06-1753</ArticleId>
            <ArticleId IdType="pubmed">17317846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ullmann TM, Liang H, Moore MD, Al-Jamed I, Gray KD, Limberg J, et al. . Dual Inhibition of BRAF and MEK Increases Expression of Sodium Iodide Symporter in Patient-Derived Papillary Thyroid Cancer Cells In Vitro. Surgery (2020) 167(1):56–63. 10.1016/j.surg.2019.04.076
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.surg.2019.04.076</ArticleId>
            <ArticleId IdType="pubmed">31585718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tavares C, Eloy C, Melo M, Gaspar da Rocha A, Pestana A, Batista R, et al. . Mtor Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and Mtorc2 Complexes for Tumor Behavior and SLC5A5 mRNA Expression. Int J Mol Sci (2018) 19(5):1448. 10.3390/ijms19051448
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms19051448</ArticleId>
            <ArticleId IdType="pmc">PMC5983778</ArticleId>
            <ArticleId IdType="pubmed">29757257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, et al. . Genomic Dissection of Hurthle Cell Carcinoma Reveals a Unique Class of Thyroid Malignancy. J Clin Endocrinol Metab (2013) 98(5):E962–72. 10.1210/jc.2012-3539
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2012-3539</ArticleId>
            <ArticleId IdType="pmc">PMC5393465</ArticleId>
            <ArticleId IdType="pubmed">23543667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tallini G, Ladanyi M, Rosai J, Jhanwar SC. Analysis of Nuclear and Mitochondrial DNA Alterations in Thyroid and Renal Oncocytic Tumors. Cytogenet Cell Genet (1994) 66(4):253–9. 10.1159/000133706
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000133706</ArticleId>
            <ArticleId IdType="pubmed">7909283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baris O, Savagner F, Nasser V, Loriod B, Granjeaud S, Guyetant S, et al. . Transcriptional Profiling Reveals Coordinated Up-Regulation of Oxidative Metabolism Genes in Thyroid Oncocytic Tumors. J Clin Endocrinol Metab (2004) 89(2):994–1005. 10.1210/jc.2003-031238
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2003-031238</ArticleId>
            <ArticleId IdType="pubmed">14764826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, et al. . Defective Oxidative Phosphorylation in Thyroid Oncocytic Carcinoma is Associated With Pathogenic Mitochondrial DNA Mutations Affecting Complexes I and III. Cancer Res (2006) 66(12):6087–96. 10.1158/0008-5472.CAN-06-0171
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-06-0171</ArticleId>
            <ArticleId IdType="pubmed">16778181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pereira L, Soares P, Maximo V, Samuels DC. Somatic Mitochondrial DNA Mutations in Cancer Escape Purifying Selection and High Pathogenicity Mutations Lead to the Oncocytic Phenotype: Pathogenicity Analysis of Reported Somatic mtDNA Mutations in Tumors. BMC Cancer (2012) 12:53. 10.1186/1471-2407-12-53
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-12-53</ArticleId>
            <ArticleId IdType="pmc">PMC3342922</ArticleId>
            <ArticleId IdType="pubmed">22299657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kurelac I, de Biase D, Calabrese C, Ceccarelli C, Ng CK, Lim R, et al. . High-Resolution Genomic Profiling of Thyroid Lesions Uncovers Preferential Copy Number Gains Affecting Mitochondrial Biogenesis Loci in the Oncocytic Variants. Am J Cancer Res (2015) 5(6):1954–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4529616</ArticleId>
            <ArticleId IdType="pubmed">26269756</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
